chemotherapy-induced febrile neutropenia

chemotherapy-induced febrile neutropenia

Item
http://www.wikidata.org/entity/Q55082384
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating FactorNivestim® (Filgrastim) Tolerance in Patients Treated by Toxic Chemotherapeutic AgentsA Multi Centre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Standard of Care Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Early StageProspective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk ChemotherapyStudy Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy.Starting Granulocyte Colony-Stimulating Factor at 1 Day vs 3 Days Following Chemotherapy in Pediatric Cancer PatientsAntibiotic Therapy With or Without G-CSF in Treating Children With Neutropenia and Fever Caused by ChemotherapyPredictive Value of ProCalcitonin for the Detection of Bacteraemia in Patients Presenting to the Emergency Department for Low Risk Chemo-induced Febrile NeutropeniaSafety and Efficacy of Ambulatory Versus In-hospital Antibiotic Treatment in Children With Febrile NeutropeniaHome Administration of NivestimTM in the Primary Prophylaxis of Chemotherapy-Induced Febrile NeutropeniaA Study to Compare Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Febrile NeutropeniaEfficacy and Safety Study With MYL-1401H and NeulastaGranulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer
P1050
Colony-stimulating factors for chemotherapy-induced febrile neutropeniaPrimary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patientsColony-stimulating factors for the prevention of chemotherapy induced febrile neutropenia in breast cancer patientsColony stimulating factors for prevention of chemotherapy induced febrile neutropenia in children with acute lymphoblastic leukaemiaMeta-Analysis and Cost Comparison of Empirical versus Pre-Emptive Antifungal Strategies in Hematologic Malignancy Patients with High-Risk Febrile NeutropeniaPredictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia.Prognostic factors for risk stratification of adult cancer patients with chemotherapy-induced febrile neutropenia: a systematic review and meta-analysis.Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study.Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?Clinical predictive models for chemotherapy-induced febrile neutropenia in breast cancer patients: a validation study.Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin's lymphoma in European and Australian clinical practiceGranulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia.Which one is a risk factor for chemotherapy-induced febrile neutropenia in childhood solid tumors: early lymphopenia or monocytopenia?Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials.Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.Incidence and impact of baseline electrolyte abnormalities in patients admitted with chemotherapy induced febrile neutropenia.Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases.2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of study results in light of NCAG/NCEPOD findingsEconomic comparison of home-care-based versus hospital-based treatment of chemotherapy-induced febrile neutropenia in children.Colony stimulating factors for chemotherapy induced febrile neutropenia.Role of lipegfilgrastim in the management of chemotherapy-induced neutropeniaPotential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study.EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.Colony-stimulating factors: clinical evidence for treatment and prophylaxis of chemotherapy-induced febrile neutropenia.Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?Empirical antimicrobial treatment for chemotherapy-induced febrile neutropenia.Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice.Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study).Retrospective survey and evaluation of first-line antibiotics for chemotherapy-induced febrile neutropenia in patients with acute myeloid leukemia.Predicting the risk of severe infection in children with chemotherapy-induced febrile neutropenia.Full-dose chemotherapy in early stage breast cancer regardless of absolute neutrophil count and without G-CSF does not increase chemotherapy-induced febrile neutropenia.Economic burden of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review.Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors.Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor.Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis in chemotherapy-induced febrile neutropenia among breast cancer and Non-Hodgkin's lymphoma patients under Taiwan's national health insurance system.Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: Protocol amendments.Management of chemotherapy-induced febrile neutropenia in pediatric oncology patients: A North American survey of pediatric hematology/oncology and pediatric infectious disease physicians.[Chemotherapy-induced febrile neutropenia: About 186 episodes. Clinical, microbiological and therapeutic characteristics].Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study).
P921
Q24193040-9E310517-EE99-4F39-87ED-F10B85CA5F14Q24198118-3B55770E-D1EE-41B9-A854-318D6844D329Q24240768-F5448379-2372-409E-9EC8-4DFB5B07100FQ24250081-9F2A78CA-33BC-4145-A78B-91FD5B5D504AQ26778187-3B48EDDE-6A41-45F9-89D8-7FCBBCC09DE8Q33390157-65BCA2C0-3DDA-46B7-8DAD-7A82213A129FQ33412051-9316104A-12B8-43BE-953F-0FCEA4C0AEDCQ33599892-8B433B77-93ED-4D79-A3B0-EDE7A39F76F5Q33756369-E9068A0B-CA89-4C7E-AF76-159DB2115957Q33778817-4BAC19A6-F82B-4D2A-B4BB-56B293568B61Q34390036-765392A6-696C-4279-91AF-8F06565A34CCQ34436603-FBBCA15A-284F-4FA5-B8AB-F9FDAEA14B05Q34519872-969168BF-FF99-4B38-BC0F-85A1517E4035Q34558598-991484D8-D8DE-47D5-A6E7-98A6EF4AC6AEQ34562182-DE8BA21B-B08E-4EB7-9DB7-4EAEC86AB776Q34575183-1CDEAC15-0342-475B-9435-27BCFB1B25EDQ34585066-8C840C03-75C8-4012-9B49-69610A64E47AQ34625316-F30B2A8B-ABB1-4D51-82FF-0BF6E03B06FEQ34627796-EBE053CA-A18F-4E88-A4FA-1B157FDCBB65Q35086942-8285B8D2-A131-4C8D-9C5A-8AB82999905DQ35199419-FC321D18-54B2-4DF7-9ACD-A5D831D7528DQ35298321-FF30D7CE-2C42-49F3-92FC-EE0A020BC03AQ35565315-ABEF4E5E-C8D6-4B2C-8B58-EC8CB9E79D1FQ36495967-4950467B-3F95-4BB4-838C-A8F9FDC974EAQ36639295-57F50727-E5D9-4A5D-AA33-20EAB4111E81Q36723903-9FD686E5-1CFF-48D6-ADD8-533DE2426A76Q36755041-810ED64E-A2E0-4277-AE92-4CCF1F7F1030Q36840636-2B193A66-F6D4-4A5E-B370-443ECEC79349Q37387974-27BB3AD6-2E5F-4908-83A3-EDEAE4E698CAQ37694581-5B59A353-B98B-4292-BDC9-93158650DD77Q37962236-BA2E5377-59BA-414B-8ED3-17A6F8D2AD40Q38109529-AEDCE0A6-D517-4CF8-BD08-46C904B7353AQ38323964-4F6D4833-B5FC-43A1-A961-0AEFD27B7A75Q38613025-FFFD6CAB-0C2D-4863-A256-E4B4AC08B095Q39297322-3DA6FDBD-EE7A-4435-A2FB-AD6D2685C2C0Q39524475-498F0A73-07B7-4F1F-974B-2F1650AC12ACQ39775083-92D3C7E2-0EBA-4387-BF71-3BE33C264174Q40117707-7B4C2AF4-491C-448E-932B-66EFB75A678CQ40139117-F88CAE48-90E5-4486-8C63-BA50C1FA8B05Q40141879-FC667CB1-FE83-4F97-AB60-8F1F084025DF
P921

chemotherapy-induced febrile neutropenia

Item
http://www.wikidata.org/entity/Q55082384
description
fever accompanied by a signifi ...... t associated with chemotherapy
@en
name
chemotherapy-induced febrile neutropenia
@en
neutropénie fébrile liée à une chimiothérapie
@fr
type
label
chemotherapy-induced febrile neutropenia
@en
neutropénie fébrile liée à une chimiothérapie
@fr
prefLabel
chemotherapy-induced febrile neutropenia
@en
neutropénie fébrile liée à une chimiothérapie
@fr
P1995
P279
P31
P486
P672
P486
P672
P1995
P279
P31
P486
P672
C15.378.553.546.184.564.750.500